Roehrborn CG. Benign prostatic hyperplasia: an overview. Rev Urol. 2005;7:S3–14.
Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104:352–60.
Management of non-neurogenic male LUTS. EAU Guidelines. Edn. presented at the EAU Annual Congress 2024.
Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2019;202:558–63. https://doi.org/10.1097/JU.0000000000000309.
Abrams P, Chapple CR, Khoury S, Roehrborn C, de la Rosette J. International Scientific Committee. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009;181:1779–87.
Robert G, Descazeaud A, Nicolaïew N, Terry S, Sirab N, Vacherot F, et al. Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate. 2009;69:1774–80.
De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schröder F, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106–17.
Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379–84.
Gravas S, De Nunzio C, Campos Pinheiro L, de León JP, Skriapas K, Milad Z, et al. Development and validation of a clinical nomogram to predict prostatic inflammation in men with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 2025;28:405–10. https://doi.org/10.1038/s41391-024-00857-5.
Sandhu JS, Bixler BR, Dahm P, Goueli R, Kirkby E, Stoffel JT, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. 2024;211:11–19. https://doi.org/10.1097/JU.0000000000003698.
Peyronnet B, Mironska E, Chapple C, Cardozo L, Oelke M, Dmochowski R, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment. Eur Urol. 2019;75:988–1000. https://doi.org/10.1016/j.eururo.2019.02.038.
Rosier PFWM, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, et al. International continence society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn. 2017;36:1243–60. https://doi.org/10.1002/nau.23124.
Irani J, Levillain P, Goujon JM, Bon, Doré B, Aubert J. Inflammation in benign prostatic hyperplasia: correlation with prostate specific antigen value. J Urol. 1997;157:1301–3.
Lombardo R, Ghezzo N, Sarcinelli L, Turchi B, Zammitti F, Franco A, et al. Post-voided residual ratio does not predict trifecta outcome after transurethral resection of prostate. Life. 2024;14:445 https://doi.org/10.3390/life14040445.
Oh MM, Choi H, Park MG, Kang SH, Cheon J, Bae JH, et al. Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction? Urology. 2011;77:167–70. https://doi.org/10.1016/j.urology.2010.05.034.
Verhovsky G, Baberashvili I, Rappaport YH, Zilberman DE, Neheman A, Gal J, et al. Bladder oversensitivity is associated with bladder outlet obstruction in men. J Pers Med. 2022;12:1675 https://doi.org/10.3390/jpm12101675.
Penna G, Fibbi B, Amuchastegui S, Cossetti C, Aquilano F, Laverny G, et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J Immunol. 2009;182:4056–64. https://doi.org/10.4049/jimmunol.0801875.
De Nunzio C, Giglio S, Stoppacciaro A, Gacci M, Cirombella R, Luciani E, et al. Autophagy deactivation is associated with severe prostatic inflammation in patients with lower urinary tract symptoms and benign prostatic hyperplasia. Oncotarget. 2017;8:50904–10. https://doi.org/10.18632/oncotarget.15144.
Vignozzi L, Gacci M, Cellai IL, Morelli A, Maneschi E, Comeglio P, et al. PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. Prostate. 2013;73:1391–402. https://doi.org/10.1002/pros.22686.
Morelli AN, Comeglio P, Filippi S, Sarchielli E, Vignozzi L, Maneschi E, et al. Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit. Prostate. 2013;73:428–41. https://doi.org/10.1002/pros.22584.
Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16:101–6. https://doi.org/10.1038/pcan.2012.44.
Vignozzi L, Cellai IL, Santi R, Lombardelli L, Morelli A, Comeglio P, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214:31–43. https://doi.org/10.1530/JOE-12-0142.
Russo GI, Vanella L, Castelli T, Cimino S, Reale G, Urzì D, et al. Heme oxygenase levels and metaflammation in benign prostatic hyperplasia patients. World J Urol. 2016;34:1183–92. https://doi.org/10.1007/s00345-015-1736-8.
Gacci M, De Nunzio C, Gravas S. Unveiling prostatic inflammation to optimize management of lower urinary tract symptoms: a discussion with experts. Biomark Med. 2023;17:739–45. https://doi.org/10.2217/bmm-2023-0365.
de Nunzio C, Franco G, Rocchegiani A, Iori F, Leonardo C, Laurenti C, et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol. 2003;169:535–9. https://doi.org/10.1097/01.ju.0000045600.69261.73.
Antunes AA, Iscaife A, Reis ST, Albertini A, Nunes MA, Lucon AM, et al. Can we predict which patients will experience resolution of detrusor overactivity after transurethral resection of the prostate? J Urol. 2015;193:2028–32. https://doi.org/10.1016/j.juro.2014.12.095.
Kim M, Jeong CW, Oh SJ. Effect of urodynamic preoperative detrusor overactivity on the outcomes of transurethral surgery in patients with male bladder outlet obstruction: a systematic review and meta-analysis. World J Urol. 2019;37:529–38. https://doi.org/10.1007/s00345-018-2402-8.
Dmochowski RR, Staskin D. Overactive bladder in men: special considerations for evaluation and management. Urology. 2002;60:56–62. https://doi.org/10.1016/s0090-4295(02)01797-1.
Ni J, Mizoguchi S, Bernardi K, Suzuki T, Kurobe M, Takaoka E, et al. Long-lasting bladder overactivity and bladder afferent hyperexcitability in rats with chemically-induced prostatic inflammation. Prostate. 2019;79:872–9. https://doi.org/10.1002/pros.23794.
Oelke M, Baard J, Wijkstra H, de la Rosette JJ, Jonas U, Höfner K, et al. Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia. Eur Urol. 2008;54:419–26. https://doi.org/10.1016/j.eururo.2008.02.017.
Bellucci CHS, Ribeiro WO, Hemerly TS, de Bessa JrJ, Antunes AA, Leite KRM, et al. Increased detrusor collagen is associated with detrusor overactivity and decreased bladder compliance in men with benign prostatic obstruction. Prostate Int. 2017;5:70–74. https://doi.org/10.1016/j.prnil.2017.01.008.
De Nunzio C, Salonia A, Gacci M, Ficarra V. Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. World J Urol. 2020;38:2771–9. https://doi.org/10.1007/s00345-020-03106-1.
Samarinas M, Gacci M, de la Taille A, Gravas S. Prostatic inflammation: a potential treatment target for male LUTS due to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2018;21:161–7. https://doi.org/10.1038/s41391-018-0039-8.